Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.93
-0.03-0.25%
At close: -
$12.10
0.171.42%
After Hours: Jun 13, 5:17 PM EDT
Comments
Loading...
Nurix Therapeutics Analyst Ratings and Price Targets | NASDAQ:NRIX | Benzinga
Nurix Therapeutics Inc has a consensus price target of $30.26 based on the ratings of 19 analysts. The high is $41 issued by Jefferies on October 11, 2024. The low is $16 issued by Leerink Partners on March 17, 2025. The 3 most-recent analyst ratings were released by Needham, Wells Fargo, and Stifel on April 29, 2025, April 9, 2025, and April 9, 2025, respectively. With an average price target of $29 between Needham, Wells Fargo, and Stifel, there's an implied 139.67% upside for Nurix Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Wells Fargo
Stifel
HC Wainwright & Co.
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Nurix Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/29/2025 | Buy Now | 123.14% | Needham | Gil Blum53% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2025 | Buy Now | 106.61% | Wells Fargo | Derek Archila63% | $32 → $25 | Maintains | Overweight | Get Alert |
| 04/09/2025 | Buy Now | 189.26% | Stifel | Stephen Willey52% | $36 → $35 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 123.14% | Needham | Gil Blum53% | $28 → $27 | Maintains | Buy | Get Alert |
| 04/02/2025 | Buy Now | 197.52% | HC Wainwright & Co. | Robert Burns46% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 32.23% | Leerink Partners | Faisal Khurshid43% | → $16 | Initiates | → Market Perform | Get Alert |
| 02/03/2025 | Buy Now | 40.5% | Morgan Stanley | Terence Flynn66% | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 01/29/2025 | Buy Now | 123.14% | RBC Capital | Gregory Renza52% | $26 → $27 | Maintains | Outperform | Get Alert |
| 01/29/2025 | Buy Now | 147.93% | JP Morgan | Eric Joseph44% | $31 → $30 | Maintains | Overweight | Get Alert |
| 01/29/2025 | Buy Now | 197.52% | Stifel | Stephen Willey52% | $34 → $36 | Maintains | Buy | Get Alert |
| 01/29/2025 | Buy Now | 131.4% | Needham | Gil Blum53% | $29 → $28 | Maintains | Buy | Get Alert |
| 01/29/2025 | Buy Now | 197.52% | HC Wainwright & Co. | Robert Burns46% | $35 → $36 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | 156.2% | Stephens & Co. | Sudan Loganathan42% | $31 → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 12/11/2024 | Buy Now | 189.26% | HC Wainwright & Co. | Robert Burns46% | $30 → $35 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 189.26% | BTIG | Jeet Mukherjee 28% | → $35 | Initiates | → Buy | Get Alert |
| 12/10/2024 | Buy Now | 139.67% | Needham | Gil Blum53% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | 189.26% | BMO Capital | Etzer Darout49% | → $35 | Initiates | → Outperform | Get Alert |
| 11/06/2024 | Buy Now | 139.67% | Needham | Gil Blum53% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 189.26% | UBS | David Dai30% | → $35 | Initiates | → Buy | Get Alert |
| 10/21/2024 | Buy Now | 139.67% | Needham | Gil Blum53% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | 147.93% | HC Wainwright & Co. | Robert Burns46% | $26 → $30 | Maintains | Buy | Get Alert |
| 10/14/2024 | Buy Now | 114.88% | RBC Capital | Gregory Renza52% | $27 → $26 | Maintains | Outperform | Get Alert |
| 10/14/2024 | Buy Now | 156.2% | Stephens & Co. | Sudan Loganathan42% | $31 → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 10/14/2024 | Buy Now | 139.67% | Needham | Gil Blum53% | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 238.84% | Jefferies | Roger Song37% | → $41 | Initiates | → Buy | Get Alert |
| 09/04/2024 | Buy Now | 147.93% | Oppenheimer | Mark Breidenbach47% | $27 → $30 | Maintains | Outperform | Get Alert |
| 08/14/2024 | Buy Now | 123.14% | Oppenheimer | Mark Breidenbach47% | $25 → $27 | Maintains | Outperform | Get Alert |
| 07/31/2024 | Buy Now | 197.52% | Truist Securities | Srikripa Devarakonda45% | → $36 | Initiates | → Buy | Get Alert |
| 07/15/2024 | Buy Now | 180.99% | JP Morgan | Eric Joseph44% | $31 → $34 | Maintains | Overweight | Get Alert |
| 07/15/2024 | Buy Now | 156.2% | Barclays | Peter Lawson43% | $20 → $31 | Maintains | Overweight | Get Alert |
| 07/12/2024 | Buy Now | 123.14% | RBC Capital | Gregory Renza52% | $26 → $27 | Maintains | Outperform | Get Alert |
| 07/12/2024 | Buy Now | 139.67% | Needham | Gil Blum53% | $31 → $29 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 114.88% | RBC Capital | Gregory Renza52% | $23 → $26 | Maintains | Outperform | Get Alert |
| 06/18/2024 | Buy Now | 114.88% | HC Wainwright & Co. | Robert Burns46% | $19 → $26 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | 156.2% | JP Morgan | Eric Joseph44% | $30 → $31 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 189.26% | Piper Sandler | Joseph Catanzaro46% | $35 → $35 | Maintains | Overweight | Get Alert |
| 05/15/2024 | Buy Now | 123.14% | Stifel | Stephen Willey52% | → $27 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 65.29% | Stephens & Co. | Sudan Loganathan42% | → $20 | Initiates | → Overweight | Get Alert |
| 04/11/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 90.08% | RBC Capital | Gregory Renza52% | $22 → $23 | Maintains | Outperform | Get Alert |
| 04/11/2024 | Buy Now | 106.61% | Baird | Joel Beatty69% | $24 → $25 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | -17.36% | Morgan Stanley | Terence Flynn66% | $9 → $10 | Maintains | Equal-Weight | Get Alert |
| 02/20/2024 | Buy Now | 57.02% | HC Wainwright & Co. | Robert Burns46% | $35 → $19 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 65.29% | Wells Fargo | Derek Archila63% | $23 → $20 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | 81.82% | RBC Capital | Gregory Renza52% | $24 → $22 | Maintains | Outperform | Get Alert |
| 02/02/2024 | Buy Now | 156.2% | Needham | Gil Blum53% | $31 → $31 | Reiterates | Buy → Buy | Get Alert |
| 11/02/2023 | Buy Now | 98.35% | RBC Capital | Gregory Renza52% | $29 → $24 | Maintains | Outperform | Get Alert |
| 10/13/2023 | Buy Now | 139.67% | RBC Capital | Gregory Renza52% | $30 → $29 | Maintains | Outperform | Get Alert |
| 10/13/2023 | Buy Now | 156.2% | Needham | Gil Blum53% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 189.26% | HC Wainwright & Co. | Robert Burns46% | $33 → $35 | Maintains | Buy | Get Alert |
| 09/07/2023 | Buy Now | 156.2% | Needham | Gil Blum53% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 172.73% | HC Wainwright & Co. | Robert Burns46% | $53 → $33 | Maintains | Buy | Get Alert |
| 07/17/2023 | Buy Now | -0.83% | Morgan Stanley | Terence Flynn66% | $11 → $12 | Maintains | Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | 106.61% | Oppenheimer | Mark Breidenbach47% | → $25 | Assumes | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | 338.02% | HC Wainwright & Co. | Robert Burns46% | → $53 | Reiterates | → Buy | Get Alert |
| 04/21/2023 | Buy Now | 156.2% | Needham | Gil Blum53% | → $31 | Reiterates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | 147.93% | RBC Capital | Gregory Renza52% | → $30 | Reiterates | → Outperform | Get Alert |
| 04/14/2023 | Buy Now | 156.2% | Needham | Gil Blum53% | → $31 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | 338.02% | HC Wainwright & Co. | Robert Burns46% | → $53 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 65.29% | Barclays | Peter Lawson43% | → $20 | Initiates | → Overweight | Get Alert |
| 02/28/2023 | Buy Now | 106.61% | Oppenheimer | Mark Breidenbach47% | → $25 | Initiates | → Outperform | Get Alert |
| 02/14/2023 | Buy Now | 156.2% | Stifel | Stephen Willey52% | $37 → $31 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | 197.52% | JP Morgan | Eric Joseph44% | $37 → $36 | Maintains | Overweight | Get Alert |
| 02/10/2023 | Buy Now | 338.02% | HC Wainwright & Co. | Robert Burns46% | → $53 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | 147.93% | RBC Capital | Gregory Renza52% | $39 → $30 | Maintains | Outperform | Get Alert |
| 02/10/2023 | Buy Now | 156.2% | Needham | Gil Blum53% | $32 → $31 | Maintains | Buy | Get Alert |
| 12/13/2022 | Buy Now | 131.4% | SVB Leerink | Andrew Berens48% | $37 → $28 | Maintains | Outperform | Get Alert |
| 10/11/2022 | Buy Now | -9.09% | Morgan Stanley | Terence Flynn66% | → $11 | Initiates | → Equal-Weight | Get Alert |
| 10/07/2022 | Buy Now | 338.02% | HC Wainwright & Co. | Robert Burns46% | $54 → $53 | Maintains | Buy | Get Alert |
| 07/12/2022 | Buy Now | 164.46% | Needham | Gil Blum53% | $38 → $32 | Maintains | Buy | Get Alert |
| 07/11/2022 | Buy Now | 346.28% | HC Wainwright & Co. | Robert Burns46% | $60 → $54 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | 164.46% | Baird | Joel Beatty69% | $41 → $32 | Maintains | Outperform | Get Alert |
| 07/08/2022 | Buy Now | 205.79% | JP Morgan | Eric Joseph44% | $46 → $37 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Nurix Therapeutics (NRIX) stock?
The latest price target for Nurix Therapeutics (NASDAQ:NRIX) was reported by Needham on April 29, 2025. The analyst firm set a price target for $27.00 expecting NRIX to rise to within 12 months (a possible 123.14% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nurix Therapeutics (NRIX)?
The latest analyst rating for Nurix Therapeutics (NASDAQ:NRIX) was provided by Needham, and Nurix Therapeutics reiterated their buy rating.
When was the last upgrade for Nurix Therapeutics (NRIX)?
There is no last upgrade for Nurix Therapeutics
When was the last downgrade for Nurix Therapeutics (NRIX)?
There is no last downgrade for Nurix Therapeutics.
When is the next analyst rating going to be posted or updated for Nurix Therapeutics (NRIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nurix Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nurix Therapeutics was filed on April 29, 2025 so you should expect the next rating to be made available sometime around April 29, 2026.
Is the Analyst Rating Nurix Therapeutics (NRIX) correct?
While ratings are subjective and will change, the latest Nurix Therapeutics (NRIX) rating was a reiterated with a price target of $27.00 to $27.00. The current price Nurix Therapeutics (NRIX) is trading at is $12.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
